Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin — Competitive Intelligence Brief

Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin (Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial. Area: Infectious Diseases.

phase 3 Antimalarial Dihydropteroate synthase, Dihydrofolate reductase, Heme detoxification pathway Infectious Diseases Small molecule

Target snapshot

Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin (Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin) — London School of Hygiene and Tropical Medicine. Sulphadoxine acts as a sulfonamide antibacterial agent, inhibiting dihydropteroate synthase, while pyrimethamine inhibits dihydrofolate reductase, and amodiaquine is a 4-aminoquinoline antimalarial that targets the malaria parasite's heme detoxification pathway. Azithromycin is a macrolide antibiotic that inhibits protein synthesis in bacteria.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin TARGET	Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin	London School of Hygiene and Tropical Medicine	phase 3	Antimalarial	Dihydropteroate synthase, Dihydrofolate reductase, Heme detoxification pathway
Coartem	LUMEFANTRINE	Novartis	marketed	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Coartem	ARTEMETHER		marketed	Antimalarial [EPC]		2009-01-01
Qualaquin	QUININE	Sun Pharm Industries	marketed	Antimalarial	Sodium channel alpha subunits; brain (Types I, II, III)	2005-01-01
Malarone	PROGUANIL	GSK	marketed	Antimalarial [EPC]		2000-01-01
Mepron	ATOVAQUONE		marketed	Antimalarial [EPC]	ATP-binding cassette sub-family G member 2	1992-01-01
Halfan	HALOFANTRINE	GSK	marketed	Antimalarial	Potassium voltage-gated channel subfamily H member 2	1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial class)

1. London School of Hygiene and Tropical Medicine · 6 drugs in this class
2. Sanofi · 3 drugs in this class
3. Epicentre · 2 drugs in this class
4. University of Oxford · 2 drugs in this class
5. · 2 drugs in this class
6. Frantz Viral Therapeutics, LLC · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Institut de Recherche pour le Developpement · 1 drug in this class
9. Centre de Recherche Médicale de Lambaréné · 1 drug in this class
10. GlaxoSmithKline · 1 drug in this class